A Phase IV Efficacy Study of Formeta Plus Carboplatin as First-Line Treatment of Advanced Non-Squamous, Non-Small Cell Lung Cancer in Iran: An Affordable Price with Clinical Benefit

BACKGROUND: This study performed to assess the efficacy and safety of Formeta (generic form of Pemetrexed) plus Carboplatin as first-line chemotherapy in advanced stage, non- squamous, non small cell lung cancer (NSCLC) in Iran. METHODS: This was a post marketing single-arm phase IV efficacy study o...

Descripción completa

Detalles Bibliográficos
Autores principales: Khosravi, Adnan, Salimi, Babak, Esfahani-Monfared, Zahra, Seifi, Sharareh, Mirtavoos-Mahyari, Hanifeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291026/
https://www.ncbi.nlm.nih.gov/pubmed/30362335
http://dx.doi.org/10.22034/APJCP.2018.19.10.2973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291026/
https://www.ncbi.nlm.nih.gov/pubmed/30362335
http://dx.doi.org/10.22034/APJCP.2018.19.10.2973

Ejemplares similares